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Intercalibrated measurements oflead in calcium supplements indicate the importance ofrigorous
analytical techniques to accurately quantify contaninant exposures in complex matrices. Without
such techniques, measurements oflead concentrations in calcium supplements may be either erro-
neouslylow, byas much as 50%, orbelowthedetection limitneededfornewpublichealth criteria
Inthis study,wedetermined the leadcontent of136brands ofsupplementsthatwerepurchasedin
1996. Thecalcium intheproductswasderivedfrom naturl sources (bonemeal, dolomite, oroyster
shell) or was synthesized andlor refined (chelated and nonchelated calcium). The dried products
were acid digested and analyzed for lead by high resolution-inductively coupled plasma-mass spec-
trometry. The method's limit ofquantitation averaged 0.06 pg/g, with a coefficient ofvariation of
1.7% and a90-100% leadrecoveryofabonemeal standard reference material. Two-thirds ofthose
calcium supplements failed to meet the 1999 California criteria for acceptable lead levels (1.5
pg/dailydose ofcalcium) in consumer products. The nonchelated synthesized and/orrefined calci-
um products, specificallyantacids and infant formulas, had the lowest lead concentrations,
from nondetectable to 2.9 pg PbIg calcium, and had the largest proportion ofbrands meetig the
new criteria (85% ofthe antacids and 100% ofthe infant formulas). Key work* antacids, bone-
meal, calcium supplements, dolomite, inductively coupled plasma-mass spectrometry (ICP-MS),
infant formulas, lead, nutritional supplements, oyster shell, vitamins. Environ Health Perspect
108:309-313 (2000). [Online 21 February 2000]
httap.//chpnetl.nies.nih.gov/docs/2000/108p309-313stelfo/abstract.html
Most Americans (> 50% of all children
under 5 and = 85% ofteenage girls) do not
ingest enough calcium (1,2) and many still
ingest too much lead (3-5). Lead, in con-
trast to calcium, is not an essential nutrient,
and it has no established toxicity threshold
concentration (6). As a biochemical analog
of calcium, lead interferes with calcium
metabolism and many of its biologic func-
tions (7-9). Recent studies indicate that low
levels of lead exposure are correlated with
irreversible fetal brain damage, hypertension,
cardiovascular disease, kidney dysfunction,
impaired bone synthesis, impaired sperm
production, and osteoporosis (6). Because
these diseases are in part attributed to pertur-
bations of the calcium cycle by lead, the
adverse effects of insufficient calcium and
elevated lead intakes are additive (6).
Several studies indicate that lead absorp-
tion, bone lead remobilization, and lead tox-
icity are all reduced with a balanced diet and
adequate calcium intake (6). These studies
have often involved dietary calcium supple-
ments because most foods have relatively low
concentrations of calcium (1). However,
some calcium supplements may also contain
relatively high amounts oflead.
The primary "natural" sources of calci-
um for nutritional supplements (bonemeal,
dolomite, and fossil oyster shells) all contain
lead. Like calcium, lead is a naturally occur-
ring element, and it is cycled through the
biosphere as a calcium analogue (10).
Although natural lead concentrations in cal-
cium matrices are usually relatively low (e.g.,
< 0.5 pg/g dry weight), the concentrations
may be markedly elevated by environmental
and industrial lead contamination. Therefore,
this paper describes a methodology for quan-
tifying that contamination.
Background
The presence oflead in calcium supplements
is of concern because some lead concentra-
tions have been measured at toxic levels.
These levels were initially detected in calcium
supplements (bonemeal) in the 1960s (11)
and precipitated a study and U.S. Food and
Drug Administration warnings of potential
lead contamination in calcium supplements
(12,13). These initial concerns were substan-
tiated in the 1980s by observations of the
association of neurologic disorders in some
patients who were taking either dolomite or
bonemeal supplements and had relatively ele-
vated lead concentrations in their hair (14).
Those observations were further substantiat-
ed by a study in the early 1990s that also
found relatively high, potentially toxic, levels
oflead in some calcium supplements (15,16).
More recently, lead contamination in a mul-
tivitamin was sufficient to confound a major
evaluation of chelation therapy in children
with blood lead concentrations > 20 pg/dL
(17). Further investigation determined that
the contaminated ingredient was ferrous
fumarate (18).
Health concerns for the relatively high
concentrations of lead in some calcium sup-
plements, and any other ingested material,
have increased with the results of recent lead
toxicity studies. These studies failed to estab-
lish a discernible threshold for some measures
of sublethal lead toxicity in humans (19).
Consequently, the level ofconcern for child-
hood lead poisoning has recently been fur-
ther lowered to blood lead concentrations of
10 pg/dL (20), and the adequacy ofeven that
new standard has been questioned (10).
All ofthese concerns have led to the enact-
ment of numerous state and federal measures
both to reduce permissible levels of environ-
mental and industrial lead exposure (6) and to
advise the public ofpotential health risks asso-
ciated with elevated lead exposures. In
California, health advisory warnings must be
put on the labels of consumer products with
lead concentrations that amount to > 1.5
pg/daily dose (21). These values are based on a
recommended adult daily dosage of 1 g calci-
um. [The recommended daily dosage ofcalci-
um for children 1-3 and 4-8 years of age is
500 and 800 mg, respectively; recommenda-
tions for older adults range from 1,000 to
1,300 mg calcium (2).] Consequently, rela-
tively sophisticated analytical techniques are
now required to accurately determine whether
such advisories are appropriate and needed for
different consumer products, including
calcium supplements.
Methods
Samples. One hundred thirty-six brands of
nutritional supplements containing calcium
were purchased in 1996 from commercial
outlets in California. The nutritional supple-
ments included calcium supplements (83
brands), vitamin-mineral supplements (27
brands), antacids (20 brands), and infant
formulas (6 brands). To determine whether
the lead concentrations ofthose diverse sam-
ples were representative of the different
products and types of calcium supplements,
we measured interlot variations for 28
brands. We analyzed two to nine (average n
= 6) lot samples ofthose products.
Address correspondence to G. Scelfo, Environmental
Toxicology, Applied Sciences 269, University of
Californiia, Santa Cruz, CA 95064 USA. Felephonie:
(831) 459-3563. Fax: (831) 459-2088. E-mail:
gscelfoa@es.ucsc.edu
We thanik S. Hibdoni anid R. Franiks for anialytical
support.
This research was partially supported by funids
from the Californiia Attoriney Genieral's Office, the
Natural Resources Defense Counicil, anid the
University of Californiia Toxic Substanices Research
and Teaching Programii.
Received 1 July 1999; accepted 26 October
1999.
Environmental Health Perspectives * Volume 108, Number 4, April 2000 309Articles * Scelfo and Flegal
The calcium used in the supplements
was either from a natural source or was syn-
thesized and/or refined (as specified on the
product label). The advertised natural calci-
um sources were bonemeal [hydroxyapatite
or calcium phosphate (CaPO4)], dolomite
[CaMg(CO3)2]' and fossil oyster shell
(CaCO3). There were two major types of
synthesized and/or refined sources of calci-
um: calcium salts and calcium bound with
various organic chelates. Calcium carbonate
(CaCO3) was the most commonly reported
calcium salt. Other synthesized products
included calcium phosphate, calcium sul-
fate, and calcium chloride. Many of the
chelated-calcium products contained one or
more of the following chelates: citrate, glu-
conate, aspartate, ascorbate, stearate, malate,
fumarate, and lysinate. Calcium citrate was
the most common ofthose chelates.
The vitamin-mineral and calcium
supplements included both natural source
calcium (bonemeal, dolomite, and fossil oys-
ter shell) and synthesized and/or refined cal-
cium (chelated and nonchelated). We ana-
lyzed 26 oyster shell brands, 9 bonemeal
brands, and 5 dolomite brands (natural
source supplements). We analyzed 33 chelat-
ed and 37 nonchelated brands (synthesized
and/or refined calcium supplements).
Sample processing. The samples were
digested in Teflon labware that had been
cleaned in a high-efficiency particulate air-
(HEPA) filtered, trace-metal-dean laboratory
to minimize contamination (19). This proto-
col involved sequentially deaning the labware
in a series ofbaths in solutions (1 week each)
and rinses (five per solution) in a three-step
order: a) we used adetergent solution (Micro;
American Scientific Products, McGraw Park,
IL) and deionized water rinses; b) we used a
6-N HCI (reagent grade) solution and ultra-
pure (Milli-Q; Millepore Corp., Bedfor, MA;
18 MQ/cm) water rinses; and c) we used a
7.5-N HNO3 (trace metal grade) solution
and ultrapure water rinses. The labware was
then air dried in a polypropylene laminar air-
flow-exhaustinghood.
After we determined the mean product
weight of 5-10 sample units (e.g., tablets or
capsules) or a 15-mL solution within each lot,
we placed aliquots of sample homogenates
(0.25-0.5 g powder or 10-15 mL liquid) in
the containers. The weighed product units
were ground into a fine powder using an
acid-cleaned mortar and pestle. Sample
aliquots were placed in acid-cleaned Teflon
screw-cap vials, dried overnight in an oven at
750C, cooled to the ambient temperature,
and then weighed.
The dried samples were dissolved in 10
mL concentrated HNO3 (trace metal grade).
When necessary, some sample vials were
placed in an ice bath and the acid was slowly
and incrementally added to control rapid
oxidation (e.g., foaming) ofthe samples. The
dissolved solutions were refluxed in the
capped vials on a ceramic hot plate (modi-
fied for trace metal analyses) for 4 hr at a low
(< 50°C) temperature to prevent excessive
foaming. The dissolved solutions were then
refluxed at a higher temperature (> 85°C)
until the solution was transparent, as specified
by the National Food Library (NFL) (22).
Finally, the samples were evaporated to dry-
ness and reconstituted in 10-mL 1N HNO3
(trace metal grade) forelemental analyses.
However, that digestion was insufficient
for lead concentration measurements by
graphite furnace atomic absorption spec-
troscopy (GFAAS). We then determined
that to accurately analyze by GFAAS, the
digested sample solutions must be both
transparent and colorless, indicating the total
breakdown of the organometal complexes.
This additional requirement substantially
increased the time for the digestion step
from 1-2 days to 7-10 days, based on a
series ofanalyses in our laboratory and cor-
roborated bythe NFL (22).
Conversely, the initial digestion to a
merely transparent solution proved sufficient
for lead concentration measurements by
high resolution inductively coupled plasma-
mass spectrometry (ICP-MS). This method
involves atomizing the solution in a plasma
with a temperature of approximately
7,000 K. The high temperature is sufficient
to destroy anyorganometal complexes before
elemental analyses, as indicated by the quan-
titative recovery (96.3 ± 4.8%) of lead in a
bonemeal standard reference material [SRM
1486; National Institute of Standards and
Technology (NIST), Gaithersburg, MD) by
ICP-MS as compared to the relatively low
(51.0 ± 5.6%) recovery by GFAAS.
Instrumental analyses. As previously
indicated, the initial attempts to measure
lead concentrations in the sample solutions
were made by GFAAS, using a SIMAA 6000
(Perkin-Elmer, Norwalk, CT) with Zeeman
background correction. The instrument was
initially calibrated with replicate analyses (n
= 7) of a Perkin-Elmer certified mixed ele-
ment standard, with lead recovery of98.9 ±
1.7%. To control for matrix effects, samples
were measured using a matrix modifier
[NH4H2PO4 + Mg(N03)2]. Although con-
centrations were calculated using the method
of standard additions, this still did not
appear to correct for all matrix effects.
Based on problems incurred with the ini-
tial GFAAS analyses, subsequent measure-
ments were made by ICP-MS. These mea-
surements proved more accurate and effi-
cient for measuring lead in calcium supple-
ments. The analyses were made with a
Finnegan MAT Element high-resolution
magnetic sector inductively coupled plasma-
mass spectrometer (Finnegan, Bremen,
Germany). To maintain high quality instru-
ment performance, solutions for ICP-MS
analysis did not exceed 0.1% total dissolved
solids. These digest solutions were made with
25- to 50-fold dilutions with a 1-pg/L (ppb)
bismuth internal standard solution in 1 N
HNO3 (i.e., 100-250 PL digestwas added to
5 mL 1 pg/L bismuth solution in trace-
metal-clean polypropylene vials). The calibra-
tion standards (0, 0.5, 1.0, 2.5, and 5.0 pg/L)
were also spiked with 1 pg/L bismuth.
We derived the lead concentration analy-
ses from instrumental scans ofthree lead iso-
topes (206Pb, 207Pb, and 208Pb) and bismuth
(209Bi). The sum ofintensities for the stable
lead isotopes was normalized to the bismuth
internal standard to correct instrumental
variations in sensitivity. Spiking the samples
with 209Bi precluded the analysis of supple-
ments containing large amounts ofbismuth,
but an alternative internal standard such as
thallium could be used for analyses of that
type ofsupplement.
Quality assurance. We used quality
assurance samples from each sample batch to
assess the precision and accuracy ofanalyses
within our laboratory. Ten percent of the
samples for each batch were digested and
analyzed in duplicate to determine the preci-
sion of the digestion, and we used replicate
instrument measurements to determine
instrument precision. We assessed replicate
dilutions ofthe digest solutions for ICP-MS
analyses to determine the precision ofpipet-
ting the sample digests. We analyzed three
solutions of a standard reference material
(NIST SRM 1486 bonemeal) concurrently
with each sample batch to quantify the accu-
racy ofthe measurements. Three procedural
blanks were analyzed concurrently with each
sample batch to quantify the sample conta-
mination associated with processing and the
detection limit.
We also usedquality assurance samples to
compare the precision and accuracy ofanaly-
ses between laboratories (Table 1). A highly
refined CaCO3 product (Specialty Minerals,
Inc., Adams, MA) was analyzed by four labo-
ratories. The laboratories included the manu-
facturer's laboratory, two independent labo-
ratories contracted by the manufacturer, and
our laboratory at the University ofCalifornia
Santa Cruz (UCSC). All of the laboratories
measured lead concentrations in the CaCO3
product using three instruments: GFAAS,
quadrapole ICP-MS, and high resolution
magnetic sector ICP-MS, respectively.
Because the sample matrices for most
calcium supplements are much more
complex than those of refined calcium sup-
plements, we also conducted a second inter-
laboratory calibration with the NFL in
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Dublin, California (Table 2). This intercali-
bration included analyses ofseven brands of
calcium supplements, with one or two sam-
ples from each of the five types of calcium
supplements. Twenty tablets ofeach product
were ground, homogenized, and dried using
trace-metal-clean techniques. At the NFL, the
sample aliquots were acid digested and ana-
lyzed by GFAAS, with Zeeman effect back-
ground correction and using the standard
additions method with a matrix modifier [Pd
+ Mg(N03)2]. At UCSC, the sample aliquots
were processed and measured by high resolu-
tion ICP-MS, as detailed in this paper.
Quality assurance comparisons with
recent measurements ofleadin calcium sup-
plements. Current levels of sensitivity
[method detection limits (MDLs) and limit
ofquantitation] and precision [coefficient of
variation (CV)] in measurements of lead in
calcium supplements are listed in Table 3,
which summarizes reported analytical para-
meters for the measurements using different
instrumentation (23-25). These instruments
include anodic stripping voltametry (ASV),
flame and graphite atomic absorption spec-
trometry (FAAS and GFAAS, respectively),
and quadrapole ICP-MS. We also used high-
resolution magnetic sector ICP-MS; those
measurements are detailed in this paper.
Results and Discussion
Two-thirds of the 136 products purchased
in 1996 failed to meet the 1999 California
criteria for acceptable lead levels in consumer
products. Although there is no statistically
significant difference (p < 0.05, analysis of
variance) between the supplement types
measured in this study, antacids had the
lowest average lead concentration with the
least variation (Table 4). We did not include
the infant formulas (all < MDLs) in the
statistical test.
Lead concentrations in synthesized
and/or refined calcium supplements. Figure
1 illustrates the distribution of lead in sup-
plements made with synthesized calcium.
Three nonchelated brands and six chelated
brands exceeded the federal limit of 7.5 pg
lead/g calcium (or 6 pg lead/800 mg calci-
um) (Figure 1). Although approximately
three-fourths ofthe nonchelated brands (n =
28) and almost two-thirds of the chelated
brands (n = 21) met theJuly 1997 California
limit of 4 pg lead/g calcium (or 3.2 pg
lead/800 mg calcium), only a small propor-
tion of these (10 nonchelated and 3 chelat-
ed) would meet the new April 1999
California limit (21) of 1.5 pg lead/g calci-
um (or 1.2 pg lead/800 mg calcium).
Generally, the lowest lead levels in all of
the materials that we analyzed were found in
the infant formulas and the antacids, which
all contained either synthesized and/or
refined calcium. Lead concentrations were
nondetectable (< 0.02 pg/g) in all infant
formulas tested, and all brands ofinfant for-
mulas and antacids were in compliance with
both the federal and the California limits for
lead that were in effect at the time ofanaly-
sis. However, three brands ofantacids, based
on these analyses, would now be in noncom-
pliance with the new (April 1999) standards
in California (Figure 1) (21).
Lead concentrations in natural calcium
supplements. Figure 2 shows the distribution
of lead concentrations in the natural source
calcium products. Two dolomite brands and
one oyster shell brand exceeded the federal
limit (Figure 2). Two of five dolomite
brands met the California July 1997 limit,
and none of these would meet the lower
April 1999 limit. Nineteen of26 oyster shell
brands met the California July 1997 limit,
only 5 ofwhich would meet the lower April
1999 limit. All nine bonemeal brands met
the federal limit; however, although eight
brands met the California July 1997 limit,
only halfofthese would meet the California
April 1999 limit.
Comparisons with previously reported
measurements oflead in nutritionalsupple-
ments. Analyses of lead in calcium supple-
ments were initiated by Capar and Gould
(12) 20 years ago. They digested the supple-
ments with perchloric acid, then measured
their lead concentrations using differential
pulsed anodic strippingvoltametry. Bourgoin
et al. (23) subsequently conducted an inter-
laboratory comparison of techniques to
measure lead concentrations in calcium sup-
plements using nitric acid or hydrochloric
acid digestions and fourdifferent instruments
(ASV, FAAS, GFAAS, and ICP-MS).
Bourgoin et al. (23) showed that the quadra-
pole ICP-MS was the most sensitive instru-
ment; GFAAS and ICP-MS were the most
precise and accurate; ASVwas relatively accu-
rate but not very sensitive or precise; and
FAAS was the least sensitive, precise, and
accurate of the four types of instruments.
Although later studies (24,25) corroborated
the relatively high sensitivity of quadrapole
ICP-MS measurements, theyalso documented
asubstantial improvement in the sensitivity of
GFAAS measurements (Table 3).
Table 1. Lead concentration (pg/g) measurements for a highly refined calcium carbonate powder for four
laboratories using three instruments.
Lead concentration (pg/g dryweight)
Laboratory Instrument Mean ± SD No.
Manufacturer GFAAS 0.187 ± 0.006 13
Independent A GFAAS 0.184± 0.005 3
Independent B Quadropole ICP-MS 0.177 ± NA 1
UCSC High resolution ICP-MS 0.167 ± 0.004 3
UCSC, University of California Santa Cruz. Interlaboratory calibration: lead analysis of refined CaCO3 powder (lot no. A-3-
070-26; Specialty Minerals, Inc., Adams, MA).
Table 2. Interlaboratory calibration: lead analysis of calcium supplements.
Sample type Sample code NFL (GFAAS) UCSC (ICP-MS) RPD
Refined, lozenge 216-ref-z 0.06 0.06 2.4
Oyster, tablet 161-oys-t 1.07 1.21 12
Oyster, tablet 94-oys-t 1.74 1.53 13
Refined, capsule 206-ref-c 0.99 0.83 17
Chelated, tablet 209-che-t 1.42 1.18 19
Bonemeal, capsule 220-bon-c 0.48 0.38 24
Dolomite, tablet 139-dol-t 2.60 1.72 41
RPD, relative percent difference. Measured lead concentration (lpg/g dryweight).
Table 3. Comparison of quality assurance parametersa with previously reported analytical lead measure-
mentsb in calcium supplements.
Instrument MDL(pg/g) LOQ (pg/g) CV (%) Recovery (%)
Anodic stripping voltametry (ASV) 0.42c 1.4 18 92
FAAS 0.50c 1.7 29 147
GFAAS 0.12c 0.40 7 100
0.042d 0.14 8 100
0.05e 0.15 11.6 80-120
ICP-MS (quadrapole) 0.01C 0.03 9 89
0.02e 0.06 4.9 80-120
ICP-MS (magnetic sector) 0.02f 0.06 1.7 90-100
Data are from the analysis of standard reference materials with a matrix comparable to calcium supplements (e.g., NIST
SRM 1486 bonemeall.
aParameters include MDL,LOQ, and CV. binstrumentation includes ASV, FAAS and GFAAS, and ICP-MS.cBourgoin et al.
(15). dSiitonen and Thompson (25). 'West Coast Analytical Service (24). fThis paper.
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Table 4. Reported lead concentrations (pg/g dryweight) in various calcium supplements by several investigators over a 20-year period.
Refined Infantformulas Infantformulas
Reference Bonemeal Dolomite Oyster shell Refined antacids Chelated (powder) (canned liquid)
Crosby 1977()11) 190 - - - -
n=1 - - - - - - -
Capar and Gould 4.16 ± 1.78
1979 (12) (1.5-8.3) - - - - - - -
n=20
Roberts 1983(14) 9.88± 7.32 5.84 7.99 - 0.30 0.35
(2-20) (0.5-19.6) _ (0.08-0.7) - -
n=8 n=8 n=3
Dabeka and - - - 88.7 (9-532) 27.4(5.8-67)
McKenzie 1987 (2 - - - - -- n= 25a n= 22b
- - - - - - 11.5(4-19) 3.5(1.2-9.8)
-- - - n=6C n=8d
Boulos and von - - - - 1.03 -
Smolenski 1988 (26) - - - - n= 1 -
Bourgoin et al. 2.67 ±2.74 1.11 ±0.71 2.11 ± 1.33 0.34 0.24 - 0.26 ±0.36
1993(23) (0.64-8.83) (0.52-2.52) (0.36-4.88) (0.04-0.92) - (0.03-1.21) - -
n=6 n=9 n=25 n=17 n=13
Siitonen and 4.27 ± 2.71 0.94 ± 0.51 0.67 ± 0.54 - - 0.60 ± 0.84
Thompson 1994(25) (1.21-6.39) (0.55-1.51) (0.17-1.26) - - (ND-1.19)
n=3 n=3 n=4 - - n=2 -
This paper (brands 0.60 ± 0.39 0.97 ± 0.49 0.88 ± 0.51 0.73 ± 1.60 0.12 ± 0.16 0.57 ± 0.54 <0.02 <0.02
purchased in 1996) (0.21-1.38) (0.39-1.56) (0.12-2.10) (0-10.05) (0.01-0.71) (0.04-2.8) n=3e n=3d
n=9 n=5 n=26 n=37 n=20 n=33
n, number of brands analyzed. Values are mean ± SD (range).
"Collected in 1980. bLead-soldered cans. CCollected in 1985. dLead-free cans. Tollected in 1996.
Some of the historical reports of mea-
surements oflead in nutritional supplements
are listed in Tables 3 and 4. Table 3 shows
the marked improvement in the precision
(CV) in lead analyses over the past 20 years.
This is notable because previous levels of
precision are insufficient for measurements
to meet the new advisory requirements for
lead exposure (i.e., 1.5 pglead/dose).
Temporal variations oflead in cakium
supplements. The data in Table 4 provide
some perspective on historic and current
variations in lead concentrations in calcium
supplements over the past 20 or more years
(11,12,14,16,25-27). As previously indicat-
ed, concerns with lead contamination in
nutritional supplements were catalyzed by
reports of remarkably elevated lead levels
(20-532 pg/g) in dolomite, bonemeal, and
infant formulas (11,14,27) and relatively
high levels (4.88 pg/g) in oyster shell supple-
ments (16). The mean lead concentrations
for each corresponding supplement type
purchased in 1996 were lower than the first
published values. There is a statistically sig-
nificant decrease (p < 0.05, t-test) in lead
concentrations in some types ofsupplements
(e.g., bonemeal, oyster shells, and infant for-
mulas), but not in others (e.g., dolomite).
There also appear to have been relatively
high variations in lead concentrations in
refined and chelated calcium supplements
throughout that period.
The apparent temporal decrease in lead
concentrations in bonemeal, oyster shells,
and infant formulas is tentatively attributed
to corresponding reductions in lead
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Figure 1. Lead in supplements and antacids pur-
chased in 1996, with synthesized and refined calci-
um (chelated and nonchelated) per800 mg calcium
(the recommended daily requirementfor children).
contamination and improvements in pro-
cessing those materials. Environmental
exposures to industrial lead have decreased
by orders of magnitude after the systematic
elimination of leaded gasoline emissions in
much of North America and Europe over
the past 20 years (28). Food and nutritional
products, such as infant formulas, are mostly
stored in lead-free cans instead of lead-sol-
dered ones. Many manufacturers that used
bonemeal for calcium supplements now use
the bones of younger bovines or equines,
which have less accumulation of industrial
lead. And, most recently, many manufactur-
ers have shifted to using only red bone
marrow because it contains less lead and is
less subject to lead contamination than outer
bone. Similarly, many manufacturers that
use fossil oyster shells for calcium supple-
ments have been using older deposits that
contain less lead. Those temporal reductions
contrast with the relative consistency in lead
-- Federal limit
8 California limitJuly 1997
c.) | - - - - California limitAril1999
E[__i -
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2 1i
Dolomite Fossil oystershell Bonemeal
Figure 2. Lead in supplements purchased in 1996,
with calcium from natural sources (bonemeal,
dolomite, and oystershell) per800 mg calcium (the
recommended daily requirementfor children).
concentrations in dolomite supplements over
the past 20 years, which may be due to the
relative homogeneity of lead concentrations
in thosedeposits (15).
Summary
These data are consistent with previous mea-
surements of lead in calcium supplements.
They indicate that some contain relatively
low concentrations of lead (< 0.5 pg/g dry
weight), whereas others contain relatively
high concentrations. Some ofthe latter con-
centrations exceed the most recent criteria
established to limit lead exposure in
California (> 1.5 pg/g).
The temporal decrease oflead concentra-
tions in some calcium supplements, indicat-
ed by previous analyses, is substantiated by
this study. This includes decreases in lead
concentrations in products derived from
bonemeal and oyster shells, but not those
derived from dolomite, over the past 20
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years. In addition, the data corroborate pre-
vious reports ofthe relatively high variations
in lead concentrations in refined and chelat-
ed calcium supplements during that period.
These new data demonstrate that rela-
tively low concentrations (< 0.5 pg/g dry
weight) may now be accurately measured in
complex calcium matrices. These matrices
require the adaptation of trace-metal-clean
techniques to minimize contamination dur-
ing sampling, processing, and analyses. The
matrices also require the adaptation ofrigor-
ous quality assurance protocols to preclude
erroneous measurements, which will tend to
underestimate lead concentrations in
calcium supplements.
As previously noted, these reported con-
centrations are for a limited number ofanaly-
ses of the brands that we collected in 1996.
The analyses were conducted before the set-
tlement oflitigation on the disdosure oflead
concentrations in calcium supplements in
California. The disclosure of lead concentra-
tions in calcium supplements catalyzed efforts
to further reduce lead concentrations in those
supplements. Consequently, lead concentra-
tions in some ofthose products may now be
lower than thevalues in this paper.
In addition, the exposure risk from lead
in calcium supplements may be relatively
small, even though the contribution of lead
from a daily dose of those supplements
(median = 2.38 pg) to the average total daily
dietary intake (5-11 pg/day) may be relative-
ly large (29). This disparity is due to the
much higher supplemental concentrations of
calcium, which decrease gastrointestinal lead
absorption (30). Several studies of factors
that influence the dietary assimilation oflead
show this decrease in lead absorption (31).
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